Document is current
Any future updates will be listed below
-
Authors
Carroll, Robert
Bortolini, Margherita
Calleja, Alan
Munro, Robin
Kong, Shiying
Daumont, Melinda J.
Penrod, John R.
Lakhdari, Khalid
Lacoin, Laure
Cheung, Winson Y.
- License Information
-
More Information
Article History
Received: 28 June 2021
Accepted: 24 February 2022
First Online: 10 March 2022
Declarations
:
: This study was conducted in accordance with the International Society for Pharmacoepidemiology (ISPE) Guidelines for Good Epidemiology Practices and the ethical principles that have their origin in the Declaration of Helsinki. The laws and regulatory requirements in Canada were followed. The protocol received approval by the Institutional Review Board (Health Research Ethics Board of Alberta). Since this was a retrospective observational study using anonymized patient data, informed consent was not required as approved by the Health Research Ethics Board of Alberta.
: Not applicable.
: RC, MJD, JRP, and KL are employees of Bristol Myers Squibb. RC and JRP also report stock ownership in Bristol Myers Squibb. MB, AC, and RM are employees of IQVIA. LL is an employee of Epi-Fit and was contracted (paid) as a consultant by Bristol Myers Squibb to support the I-O Optimise initiative. SK reports no relevant conflicts of interest. WYC reports receipt of research funding from Bristol Myers Squibb.
